SHR-3836

· Shanghai Hengrui Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SHR-3836, covering 2026-03-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of SHR-3836 in Patients With Multiple Myeloma [Phase 1]